Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic disease that causes kidney failure and accounts for 10% of all patients who are on renal replacement therapy. However, the marked phenotypic variation between patients who carry the same PKD1 or PKD2 mutation suggests that nonallelic factors may have a greater influence on the cystic phenotype. Endothelin-1 (ET-1) transgenic mice have been reported to develop profound renal cystic disease and interstitial fibrosis without hypertension. The hypothesis that ET-1 acts as a modifying factor for cystic disease progression was tested in an orthologous mouse model of ADPKD (Pkd2 WS25/؊ ). Four experimental groups (n ‫؍‬ 8 to 11) were treated from 5 to 16 wk of age with the highly selective orally active receptor antagonists ABT-627 (ETA) and A-192621 (ETB) singly or in combination. Unexpected, ETB blockade led to accelerated cystic kidney disease. Of significance, this was associated with a reduction in urine volume and sodium excretion and increases in urine osmolarity and renal cAMP and ET-1 concentrations. The deleterious effect of chronic ETB blockade was neutralized by simultaneous ETA blockade. ETA blockade alone resulted in a significant increase in tubular cell proliferation but did not alter the cystic phenotype. It is concluded that the balance between ETA and ETB signaling is critical for maintaining tubular structure and function in the cystic kidney. These results implicate ET, acting via vasopressin-dependent and independent pathways, as a major modifying factor for cystic disease progression in human ADPKD. A utosomal dominant polycystic kidney disease (AD-PKD) causes kidney failure in 10% of all patients who are on renal replacement therapy and is caused by mutations in PKD1 or PKD2 (1). The ADPKD proteins polycystin-1 and polycystin-2 function as a complex and regulate multiple signaling pathways to maintain normal tubular structure and function (2). Although a weak phenotype-genotype correlation for renal survival has been reported for PKD1, it is apparent that nonallelic factors such as genetic modifying loci and/or environmental factors have a greater influence on the cystic phenotype (3,4). These factors probably account for the marked intrafamilial phenotypic variability that sometimes is seen in PKD1 or PKD2 pedigrees (5,6).
A utosomal dominant polycystic kidney disease (AD-PKD) causes kidney failure in 10% of all patients who are on renal replacement therapy and is caused by mutations in PKD1 or PKD2 (1) . The ADPKD proteins polycystin-1 and polycystin-2 function as a complex and regulate multiple signaling pathways to maintain normal tubular structure and function (2) . Although a weak phenotype-genotype correlation for renal survival has been reported for PKD1, it is apparent that nonallelic factors such as genetic modifying loci and/or environmental factors have a greater influence on the cystic phenotype (3, 4) . These factors probably account for the marked intrafamilial phenotypic variability that sometimes is seen in PKD1 or PKD2 pedigrees (5, 6) .
The endothelins (ET-1, ET-2, and ET-3) are a family of multifunctional peptides with potent effects on BP, renal function, and cellular behavior. Although ET-1 originally was purified as a highly potent endothelial-derived vasoconstrictor (7), many other cell types, especially in the kidney, can synthesize and bind ET-1, suggesting a range of other functions (8, 9) . Two ET receptor subtypes, ETA and ETB, have been shown to mediate ET-1 action but often with opposing effects (10, 11) . During development, ET-1 (acting via ETA receptors) and ET-3 (acting via ETB receptors) are essential for the development of neural crest-derived tissues (12, 13) .
Several lines of evidence had suggested that ET-1 might participate in ADPKD disease progression. Crucially, ET-1 transgenic mice were reported by two groups to develop pronounced renal cystic phenotype without hypertension (14, 15) . In these studies, kidney ET-1 levels were only modestly elevated (two-to three-fold). Elevated concentrations of immunoreactive ET-1 have been found in ADPKD cyst fluid (16) and immunoreactive ET-1 detected in ADPKD cyst epithelium (17) . An increase in renal ET-1 gene expression has been documented in two rodent cystic models (18, 19) .
The availability of new highly selective orally active nonpeptide ET receptor antagonists provided us with useful tools to study ET receptor function in ADPKD (20) . Our initial hypothesis was that selective ETB blockade might be beneficial in slowing cystic disease progression because tubular ETB receptors had been shown to mediate mitogenesis (21) . However, ETA (but not ETB) receptor expression also is upregulated markedly in human ADPKD kidney (17) . ETA receptors have been shown to mediate mitogenesis in other cell types (22) . To clarify the potential role of ET-1 as a modifying factor in ADPKD, we used an orthologous model, the Pkd2 WS25/Ϫ mouse, to investigate the effect of selective ETA and ETB receptor blockade on disease progression.
Materials and Methods

Experimental Animals
Homologous recombination at exon-1 of the Pkd2 locus resulted in two pkd2 alleles, ws183 (Ϫ) and ws25 (19 
Experimental Drugs
Two selective orally active, nonpeptide ET receptor antagonists, ABT-627 and A-192621, were obtained from Abbott Laboratories (Abbott Park, IL). The potency and the selectivity of ABT-627 for the ETA receptor and that of A-192621 for the ETB receptor are among the highest of any known ET receptor antagonist both in vivo and in vitro (20, 24, 25) . The IC 50 of ABT-627 for ETA and ETB are 0.055 and 84.4 nM, respectively; A-192621 for ETA and ETB are 4280 and 4.54 nM, respectively. The IC 50 of either antagonist therefore was at least 1000-fold higher for one receptor subtype compared with the other (20) .
In Vivo Antagonism of the Pressor Effect of ET-1 and Sarafotoxin-6c in Normal Mice
After a pilot study to assess tolerability of wild-type mice (n ϭ 6) to vehicle (0.25 M NaHCO 3 ) and their daily fluid intake (3.0 ml/20 g body wt per 24 h), we decided to administer the antagonists in the drinking water. In a previous study, the effect of sodium bicarbonate on cystic disease severity in Pkd2 ws25/Ϫ mice was neutral (26) .
To assess the effectiveness of oral administration, we first studied the pressor effect of ET-1 (ETA and ETB agonist) and sarafotoxin-6c (SX6c; ETB agonist) in wild-type C57BL/6 mice (n ϭ 4 per group) that were fed ABT-627 (10 mg/kg per d), A-192621 (30 mg/kg per d), or vehicle (0.25 M NaHCO 3 ) in the drinking water for 7 d before study. The dosages chosen were based on the ED 50 values for each compound in blocking ET-1 or SX6c induced pressor responses in the rat (24, 25) . On the day of the experiment, mice were anesthetized and the trachea was cannulated. The right jugular vein was cannulated for intravenous infusion of saline and recording of mean arterial pressure performed via a pressure transducer (Spectramed; Statham, Oxnard, CA) in the left carotid artery.
Luciferase Assay
We used the Dual-Luciferase Reporter Assay (Promega, Madison, WI) to test the efficacy and the selectivity of ABT-627 and A-192621 to block ETA-or ETB-stimulated cAMP-mediated signal transduction. The plasmids pMPSV/CMV-ETA and pMPSV/CMV-ETB, which express full-length human ETA and ETB cDNA, were obtained from Dr. Bernard Haendler (Schering, Berlin, Germany) (27) . HEK-293 cells were transiently transfected using a calcium phosphate kit (Invitrogen, Carlsbad, CA) according to the manufacturer's instruction. After overnight incubation, the cells were pretreated with ABT-627 and A-192621 in the presence of 0.1 mM 3-isobutyl-1-methylxanthine (Acros Organics; Fisher Scientific UK, Loughborough, UK) for 30 min before ET-1 stimulation for 4 h.
Experimental Groups
The four experimental groups were vehicle (NaHCO 3 0.25 M; n ϭ 9), ABT-627 (10 mg/kg per d; n ϭ 11), A-192621 (30 mg/kg per d; n ϭ 8), and combined ABT-627 and A-192621 (n ϭ 8). Mice were treated from 5 to 16 wk of age. The dosages of ABT-627 and A-192621 chosen were shown to be effective in previous studies (28) . Mice were housed at constant temperature (21°C) and humidity (45%) on a 12-h light/dark cycle and had free access to drinking water and standard laboratory diet. Terminal liver weight or combined kidney weight was expressed as a percentage of total body weight (fractional liver or kidney weight). Half of each kidney was fixed in 10% neutral-buffered formalin, and the other half was snap-frozen in liquid nitrogen and stored at Ϫ80°C until further analysis. All experiments were carried out according to Home Office regulations (Animal Scientific Procedure Act 1986, UK).
Histomorphometric Analysis and Fibrosis Score
Four-micron transverse kidney sections were stained with hematoxylin and eosin for histomorphometric analysis. To differentiate between cysts and normal tubular profiles, only epithelial-lined cavities of the size of a glomerulus (approximately 6000 m 2 ) or larger were counted as cysts (29) . The percentage of cystic area and fibrosis score were estimated as described previously (30) . For each mouse, both kidneys were included in all histologic analyses and analyzed in a singleblinded manner.
Immunohistochemistry CD45-and F4/80-positive cells were detected on paraffin sections after antigen retrieval using previously published protocols (30) . Antibodies to CD45 and F4/80 were purchased from Serotec (Oxford, UK) and BD Pharmingen (Oxford, UK), respectively. The number of CD45-positive leukocytes or F4/80-positive macrophages in each renal section was counted in 10 consecutively selected nonoverlapping fields of renal cortex and medulla at ϫ200 magnification. Data are expressed as the number of positive staining cells (mean Ϯ SEM) per mm 2 (31) .
Assessment of Apoptosis
Apoptotic cells in kidney sections were detected by the terminal deoxynucleotidyl transferase-mediated digoxigenin-deoxyuridine nick-end labeling (TUNEL) method (Chemicon, Temecula, CA) following the manufacturer's protocol. The apoptotic index was defined as the number of TUNEL-positive cells per section in 10 sequentially selected nonoverlapping fields (ϫ200 magnification) of renal cortex and medulla, expressed per mm 2 .
5-Bromo-2Ј-Deoxyuridine Incorporation
5-Bromo-2Ј-deoxyuridine (BrdU) incorporation was used to assess the degree of cellular proliferation in vivo. Four hours before harvest, mice were administered an intraperitoneal injection of 3 mg BrdU/100 g body wt. BrdU-labeled cells in both kidneys were detected using an anti-BrdU mAb (Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA). The proliferative index (PI) was defined as the number of BrdU-positive cells in 10 sequentially selected nonoverlapping fields (ϫ200 magnification) of renal cortex and medulla, expressed per mm 2 .
BP Measurements
Measurements of systolic BP (SBP) were performed in conscious, restrained mice, using an automated system with an automatic tail-cuff inflator and a built-in photoelectric sensor (Visitech Systems, Apex, NC). Recordings using this method have been shown to correlate closely to intra-arterial measurements (32) . The SBP and pulse rate were the average of those measured at weeks 10 and 16.
Urine and Blood Chemistry
One week before mice were killed, 24-h urine collections were obtained from individual mice that were housed temporarily in metabolic cages. Plasma and urine samples were stored at Ϫ80°C until use. Urine sodium and blood urea and sodium levels were assayed by an auto-analyzer (VITROS 250; Chemistry Systems, Rochester, NY), and urine osmolarity was measured on a 3300 Advanced Micro-Osmometer (Advanced Instruments, Norwood, MA) at the Department of Clinical Biochemistry, Sheffield Children's Hospital. Twenty-four-hour urine volumes and sodium excretion were expressed per 20 g of body weight as described previously (33) .
ELISA of ET-1 and cAMP
Renal ET-1 concentrations were measured on frozen kidney tissue homogenates using a commercial ET-1 ELISA kit (Cayman Chemical, Ann Arbor, MI) as described previously (34) . For renal cAMP estimations, a cAMP ELISA system without acetylation (Biomedical Technologies, Stoughton, MA) was used. Results from both assays were expressed per wet weight of tissue (15, 35) .
Statistical Analyses
Values are expressed as means Ϯ SEM. Comparison between groups was performed by ANOVA followed by Dunnett multiple comparison test. Values that were not normally distributed were analyzed by Kruskal-Wallis test followed by Dunn multiple comparison test. Correlation analyses used the Pearson correlation test. P Ͻ 0.05 was considered statistically significant.
Results
Efficacy and Selectivity of ET Receptor Antagonists In Vitro and In Vivo
In ETA-transfected cells, 0.1 M ABT-627 blocked the cAMP reporter activity that was induced by ET-1 (1 nM) by Ͼ50%, whereas A-192621 was ineffective up to 100 M ( Figure 1A) . Conversely, in ETB-transfected cells, A-192621 inhibited the ET-1-stimulated (100 nM) cAMP reporter activity dosage dependently (1 to 100 M), but ABT-627 had no inhibitory effect up to 10 M ( Figure 1B) .
In vehicle Figure 1C) . The ETB-mediated pressor response was unaffected (36) . Similarly, an intravenous bolus of SX6c (20 ng), an ETB-specific agonist, induced a 15-mmHg increase in vehicle-treated mice, but the pressor response was abolished in mice that were pretreated with A-192621 (30 mg/kg per d) for 7 d (Figure 1D ). These results confirmed the efficacy and the selectivity of ABT-627 and A-192621 and demonstrated the effectiveness of oral administration.
Chronic Administration of ET Receptor Antagonists and Cystic Disease
Unexpected, Pkd2
WS25/Ϫ mice that were treated with A-192621 for 12 wk developed a more severe cystic phenotype, as reflected by an increase in kidney size (Figure 2) , fractional kidney weights (Table 1) , and cystic area ( Figure 2M ). Fractional liver weights were not significantly different between the groups (Table 1) . A two-way ANOVA revealed no significant interaction between treatment and gender; gender itself had no significant effect on kidney weights. A small reduction in total body weight was observed in the ETB group (Table 1) . Of interest, all of these changes were normalized by concurrent ETA blockade.
Renal Fibrosis, Leukocyte Accumulation, and Macrophage Infiltration
In the ETB group, renal fibrosis scores were increased markedly ( Figure 3D ) with a parallel increase in interstitial CD45-positive leukocytes ( Figure 3H ). Surprising, a significant reduction in the number of interstitial F4/80-positive macrophages was observed in the ETA group ( Figure 3L ) despite an unchanged number of CD45-positive leukocytes.
Figure 2. Effect of ET receptor blockade on cystic disease progression in Pkd2
WS25/Ϫ mice. Representative kidney cross-sections (hematoxylin and eosin) and gross kidney appearances from affected Pkd2 WS25/Ϫ mice that were treated from 5 to 16 wk of age with vehicle alone (A, E, and I), ETA (B, F, and J), ETB (C, G, and K), and combined ETA/ETB (D, H, and L) receptor antagonists. The percentage of cystic area was significantly greater in the ETB-treated group (M). **P Ͻ 0.01 (ETB versus control). Data are means Ϯ SEM (n ϭ 8 to 11). ETAB, combined ETA/ETB blockade. Magnification, ϫ20.
Tubular Proliferation and Apoptosis
We observed prominent BrdU labeling in undilated kidney tubules and only rarely in cyst epithelium (data not shown). There was a three-fold increase in tubular PI in the ETA group compared with controls despite the similar cystic phenotype in these two groups (Figure 4, A through D) . Despite the more severe cystic phenotype in the ETB group, tubular PI was unchanged. Of note, concomitant blockade of ETB abolished the increase that was observed after ETA blockade. Conversely, a trend toward higher apoptosis scores (P ϭ 0.09) was observed in the ETB group (Figure 4, E and F) . This was normalized, however, by combined ETA and ETB blockade. BrdU-or TUNEL-positive cystic and interstitial cells were sparse in all groups and therefore were not quantified.
Renal Function and Salt and Water Excretion
Overall terminal renal function as measured by plasma urea concentrations was significantly worse in the ETB group (Table  1) . Daily food and fluid intake did not differ significantly between the groups (data not shown). However, there was an unexpected reduction in 24-h urine volumes and sodium excretion in the ETB group with a corresponding increase in urine osmolarity ( Figure 5 ). Again, all of these changes were normalized by combined ETA blockade.
BP and Pulse Rate
No significant difference was found among all four groups for mean SBP and pulse rate as measured by tail-cuff plethysmography at weeks 10 and 16 (Table 1) .
Renal Content of cAMP and ET-1
Significant increases in kidney ET-1 and cAMP content were found only in the ETB group (Table 1 ). The two-fold increase in ET-1 after ETB blockade is similar to what has been described in the cystic kidneys of ET-1 transgenic mice (15) . There were highly significant correlations between ET-1 concentrations and a number of disease markers, such as fractional kidney weight, cystic index, fibrosis score, CD45 cell number, and tubular apoptotic index (Table 2) . A significant correlation was detected between cAMP and the fibrosis score, although a correlation with the cystic index just failed to reach significance (P ϭ 0.05; Table 2 ).
Discussion
Because ETB receptors had been shown to mediate tubular cell proliferation in vitro (12), we hypothesized that ETB receptor blockade would decrease tubular cell proliferation, a prominent early feature in human ADPKD and many rodent PKD models and potentially a precursor to cyst formation (30, 37) . Exacerbation of the renal cystic phenotype of Pkd2 WS25/Ϫ mice that were treated with ETB antagonists therefore was unexpected. Striking, simultaneous ETA blockade reversed the severe changes that were seen after ETB blockade alone, although ETA blockade alone did not alter the cystic phenotype of Pkd2 WS25/Ϫ mice. These findings indicate that the balance between ETA and ETB activation is critical for maintaining tubular structure and function in the ADPKD kidney. Moreover, because changes in tubular cell proliferation did not correlate directly with cystic disease progression (i.e., increased PI in ETA treated, unchanged PI in ETB treated), it seems clear that other pathogenic factors may have become critical in the accelerated disease progression that resulted from ETB blockade. These could include an increase in tubular apoptosis, interstitial inflammation, matrix deposition, or cyst fluid accumulation (1). The major underlying mechanism of cyst initiation in the Pkd2 WS25/Ϫ mouse is by a two-hit model (23) . Our results, however, demonstrate that cyst growth can be altered experimentally (both positively and negatively) in PKD2 by nonallelic modifying factors, independent of the rate of somatic mutation.
Although both ET subtypes are present in the kidney, ETB Figure 5 . Effect of ET receptor blockade on urine volume, osmolarity, and sodium excretion. Bar graphs show urine volume (A), urine osmolarity (B), and sodium excretion (C) in Pkd2 WS25/Ϫ mice that were treated with ET receptor antagonists or vehicle (control). ETB blockade significantly reduced urine volumes, increased urine osmolarity, and decreased urine sodium excretion, effects that were normalized by simultaneous ETA blockade. *P Ͻ 0.05, **P Ͻ 0.01 versus controls. receptors are the predominant tubular subtype, especially in the medullary collecting ducts, where ET-1 synthesis also is the highest (38, 39) . Figure 6 summarizes how several possible mechanisms could be responsible for the detrimental effect of ETB blockade in cystic Pkd2 WS25/Ϫ kidneys. Recent genetic studies that used collecting duct-specific knockouts demonstrated a physiologic role for ET-1 acting via ETB receptors in regulating sodium and water excretion in the collecting duct (40, 41) . ETB activation inhibits vasopressin action, thereby promoting diuresis and blocking sodium reabsorption by inhibiting Na ϩ -K ϩ -ATPase and/or epithelial sodium channel (38, 39) .
ETA activation seems to oppose the inhibitory effect of ETB on vasopressin action by unclear mechanisms but, unlike ETB, has no effect on sodium transport (40) . ETB blockade would potentiate vasopressin action in the collecting duct and promote sodium reabsorption. Consistent with this possibility, we observed significant reductions in water and sodium excretion after ETB blockade. In recent landmark studies, a vasopressin 2 receptor antagonist was effective in retarding the progression of cystic disease in several rodent models, including the Pkd2 WS25/Ϫ mouse (42, 43 ). An enhancement of vasopressin action therefore could be a major contributor to the accelerated disease progression after ETB blockade.
A second possible mechanism is that ETB blockade may redirect ET-1 to unopposed ETA receptors to induce fibrosis, inflammation, apoptosis, and vasoconstriction by vasopressinindependent pathways. ETA receptor antagonism has been effective in slowing disease progression in several models of chronic kidney disease (44 -46) . The number of interstitial CD45-positive leukocytes was increased in the ETB group, but there were fewer F4/80-positive macrophages in the ETA group. Therefore, proinflammatory (ETA) and anti-inflammatory (ETB) actions of ET-1 may be mediated by different receptor subtypes in the cystic kidney.
A third possibility is that a reduction in ET-1 clearance that is mediated by ETB receptors would lead to increased kidney ET-1 concentrations, which in turn could potentiate ETA action (47) . Indeed, renal ET-1 concentrations were elevated significantly in the ETB group. However, the increase also could have resulted from an increase in ET-1 synthesis from cystic cells because ETA antagonism abrogated the increase that was seen with ETB blockade alone.
The increase in tubular cell proliferation after ETA blockade (and its normalization by concomitant ETB blockade) is consistent with previous studies that showed that ETB receptors mediate tubular mitogenesis in vitro (21) . Male heterozygous (cy/ϩ) Han:SPRD rats that were treated with a different ETA antagonist (LU135252) developed increased tubular cell proliferation and an associated increase in cyst growth (48) . Although we observed a similar increase in tubular cell proliferation after ETA blockade, the overall effect on cyst progression was neutral. This difference could relate to differences in the origin of cysts from different nephron segments and the mechanisms that govern cyst progression. For instance, cysts arise mainly from the proximal tubules in male Han:SPRD PKD rats but predominantly affect the distal tubules in PKD2 WS25/Ϫ mice (and human ADPKD) (23, 49) . Our results are reminiscent of the contrasting effects of sodium bicarbonate administration on cyst formation in the Han:SPRD rat (beneficial) but not in other models, such as CD1-pcy/pcy, Pck rat, or the Pkd2 WS25/Ϫ mouse (26, 50, 51) . ETA blockade in the Han:SPRD PKD rat also resulted in an increase in tubular apoptosis and interstitial fibrosis (48) . These features were not observed in Pkd2 WS25/Ϫ mice ( Figures 3 and 4) and further suggest different underlying mechanisms of cyst growth or disease progression between the two models.
Like vasopressin receptor blockade, no changes in liver weights were found after ET receptor blockade. A small, nonsignificant elevation in mean SBP (3 mmHg) was noted in the ETB group. The structural changes that we observed after ETB blockade therefore are unlikely to be related to significant changes in BP.
Conclusion
ETB blockade accelerated cyst growth and disease progression in the Pkd2 WS25/Ϫ mouse, an orthologous murine model of human ADPKD. Because all changes were normalized by combined ETA and ETB blockade, the deleterious effect of chronic ETB blockade in Pkd2 WS25/Ϫ mice seems to be mediated largely through the unopposed action of renal ETA receptors. These findings implicate ET as a major modifying factor for cystic disease progression in human ADPKD. We thank Stefan Somlo for the gift of Pkd2 mutant mice, Bernard Haendler for the ET receptor plasmids, and Abbott Laboratories for supplying ET receptor antagonists.
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